BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30951236)

  • 1. iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
    Jézéquel P; Guette C; Lasla H; Gouraud W; Boissard A; Guérin-Charbonnel C; Campone M
    Proteomics; 2019 Nov; 19(21-22):e1800484. PubMed ID: 30951236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.
    Jézéquel P; Kerdraon O; Hondermarck H; Guérin-Charbonnel C; Lasla H; Gouraud W; Canon JL; Gombos A; Dalenc F; Delaloge S; Lemonnier J; Loussouarn D; Verrièle V; Campone M
    Breast Cancer Res; 2019 May; 21(1):65. PubMed ID: 31101122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
    Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
    Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
    Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening and identification of potential biomarkers in triple-negative breast cancer by integrated analysis.
    Guo J; Gong G; Zhang B
    Oncol Rep; 2017 Oct; 38(4):2219-2228. PubMed ID: 28849078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer.
    Müller M; Güth U; Varga Z; Reeve K; Bjelic-Radisic V; Fleisch M; Tausch CJ; Elfgen C
    Anticancer Res; 2020 Apr; 40(4):2125-2131. PubMed ID: 32234905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
    DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
    Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Multi-Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal-Like Triple-Negative Breast Cancer.
    Jin MS; Lee H; Woo J; Choi S; Do MS; Kim K; Song MJ; Kim Y; Park IA; Han D; Ryu HS
    Proteomics Clin Appl; 2018 Sep; 12(5):e1700125. PubMed ID: 29476606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
    Kalecky K; Modisette R; Pena S; Cho YR; Taube J
    BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.
    Li Y; Kong X; Wang Z; Xuan L
    J Cell Mol Med; 2022 Mar; 26(5):1351-1362. PubMed ID: 35150062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.
    Velloso FJ; Campos AR; Sogayar MC; Correa RG
    BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
    Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
    J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine.
    Golubnitschaja O; Filep N; Yeghiazaryan K; Blom HJ; Hofmann-Apitius M; Kuhn W
    Amino Acids; 2018 Apr; 50(3-4):383-395. PubMed ID: 29249020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
    Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
    Front Immunol; 2020; 11():560074. PubMed ID: 33304345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.